Associated tags: FDA, Woman, Endometriosis, Gynaecology, Aspira, Ovarian cancer
Locations: NEW YORK, UNITED STATES, MASSACHUSETTS, GEORGIA, CHICAGO, ILLINOIS, FLORIDA, CANADA, KENYA, AUSTIN, TX, TEXAS
AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024.
Key Points:
- AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024.
- Management will also host a conference call at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update.
- Details for the call are as follows:
Conference Call & Webcast Details:
AUSTIN, Texas, May 07, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of two peer-reviewed manuscripts.
Key Points:
- AUSTIN, Texas, May 07, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of two peer-reviewed manuscripts.
- The findings of this study demonstrate that use of OvaWatch® to stratify risk in patients with an adnexal mass might help to reduce surgical backlogs and unnecessary surgical referrals.
- “Today, we mark the publication of additional clinical data to support the use of OvaWatch for the assessment of ovarian cancer risk for women with an adnexal mass,” said Nicole Sandford, Chief Executive Officer of Aspira.
- Clinicians have long sought a better tool to develop an appropriate care plan for these women, and OvaWatch provides it.”
“The publication of these manuscripts, along with last week’s announcement to make OvaWatch available for testing over time, is the latest example of Aspira keeping its promises to our stakeholders.
Anthem Blue Cross will provide coverage for its commercial and government lines of business, including Medicare Advantage and Medicaid, which represents a total of approximately six million covered lives in California.
Key Points:
- Anthem Blue Cross will provide coverage for its commercial and government lines of business, including Medicare Advantage and Medicaid, which represents a total of approximately six million covered lives in California.
- “We are very pleased to add Anthem Blue Cross to our list of payers providing coverage for our OvaSuite portfolio, which provides a clear benefit to physicians in their clinical assessment of women with adnexal masses,” said Torsten Hombeck, Chief Financial Officer of Aspira.
- Our strategic focus on payer adoption continues to gather momentum.”
Anthem is a leading health company dedicated to improving lives and communities.
- Through its affiliated companies, Anthem serves more than 118 million people, including more than 45 million within its family of health plans.
Research,
Ovarian cancer,
California Department,
Conference call,
Conference,
Development,
MicroRNA,
Artificiality,
Patient,
Travel,
Cancer,
Information technology,
AUP,
Society,
Gynaecology,
AACR,
Poster,
Medicare,
Marketing,
CMS,
Human resources,
Federal,
Medi-Cal,
Cryptocurrency AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2023.
Key Points:
- Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements.
- Aspira will be reimbursed at a rate of $897 for all Ova1Plus tests processed for Medi-Cal patients meeting applicable coverage requirements.
- Gross profit margin was 57.5% for the year ended December 31, 2023, compared to 52.8% for the year ended December 31, 2022.
- Subsequent to the end of the quarter, Aspira raised $5.5 million in gross proceeds in a registered direct offering and concurrent private placement.
AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended December 31, 2023, on Thursday, March 28, 2024.
Key Points:
- AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended December 31, 2023, on Thursday, March 28, 2024.
- Management will also host a conference call at an updated time of 8:30 am ET to discuss financial results and provide a corporate update.
- Details for the call are as follows:
Conference Call & Webcast Details:
AUSTIN, Texas, March 21, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference taking place in New York City on April 3-4, 2024.
Key Points:
- AUSTIN, Texas, March 21, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the MedInvest Biotech & Pharma Investor Conference taking place in New York City on April 3-4, 2024.
- Management will be available for one-on-one meetings with investors who are registered for the conference.
Georgetown University Law Center,
Ovarian cancer,
Development,
Acceleration,
California State University,
Luminex Corporation,
Information technology,
Standard of care,
Senior,
Respiratory disease,
University,
Gynaecology,
Woman,
Doctor of Philosophy,
Research and development,
Endometriosis,
Drug development,
Dana–Farber Cancer Institute,
Therapy,
Amgen,
DIA,
Human resources,
Medical device AUSTIN, Texas, March 18, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has expanded its senior management team with the addition of Sandra Milligan, M.D., J.D. as President effective April 1, 2024. Dr. Milligan will report to Nicole Sandford, who will remain CEO. The Company has also promoted Dr. Todd Pappas, Vice President of Research & Development, to lead the Company’s product development team reporting directly to Dr. Milligan, following the departure of Dr. Jody Berry.
Key Points:
- The Company has also promoted Dr. Todd Pappas, Vice President of Research & Development, to lead the Company’s product development team reporting directly to Dr. Milligan, following the departure of Dr. Jody Berry.
- She has demonstrated success in supporting pipeline and product development in both oncology and non-oncology disease areas, with recent emphasis in women’s health.
- Dr. Milligan is a known and respected leader in women’s health who drives cross-functional strategies to achieve corporate success.
- As President, Dr. Milligan will be a key member of the executive leadership team with direct responsibility for the Research and Development, Operations, Information Technology, and Human Resources functions.
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024.
Key Points:
- AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months and year ended December 31, 2023 on Thursday, March 28, 2024.
- Management will also host a conference call at 4:30 pm to discuss financial results and provide a corporate update.
- Details for the call are as follows:
Conference Call & Webcast Details:
Retrieved on:
Thursday, February 22, 2024
AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference taking place in New Orleans, Louisiana on February 29 to March 2, 2024.
Key Points:
- AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference taking place in New Orleans, Louisiana on February 29 to March 2, 2024.
- Management will be available for one-on-one meetings with investors who are registered for the conference.
Retrieved on:
Monday, February 12, 2024
AUSTIN, Texas, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a late-breaking poster presentation at the upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI) to be held in Vancouver, Canada on March 12-16, 2024.
Key Points:
- AUSTIN, Texas, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a late-breaking poster presentation at the upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI) to be held in Vancouver, Canada on March 12-16, 2024.
- “Endometriomas are among the most common forms of endometriosis, impacting millions of women.
- The presentation of data that is foundational to our EndoCheckSM offering at this distinguished conference is a major milestone for our plan to launch the first noninvasive diagnostic test for this debilitating disease,” said Nicole Sandford, Chief Executive Officer of Aspira.
- Details of the poster presentation are as follows:
